VEA
ATXS

Virtus ETF Advisers’s Astria Therapeutics ATXS Stock Holding History

Virtus ETF Advisers’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-7,247
Closed -$64.8K – 455
2024
Q4 		$64.8K Buy
+7,247
New +$77K 0.03% 423

Other funds holding ATXS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Virtus ETF Advisers's ATXS Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Astria Therapeutics (ATXS) in Q1 2025, closing a stake of 7,247 shares — an estimated $64.8K sold.

Virtus ETF Advisers first reported a position in ATXS in Q4 2024 and held it in 1 quarter. The position peaked at $64.8K in Q4 2024. 115 funds tracked by Wall St. Rank hold ATXS as of Q1 2025.

  • Virtus ETF Advisers reported no remaining Astria Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 7,247 Astria Therapeutics shares in Q1 2025, an estimated $64.8K.
  • Virtus ETF Advisers first reported a position in Astria Therapeutics in Q4 2024 and held it in 1 quarter.
  • Virtus ETF Advisers's Astria Therapeutics position peaked at $64.8K in Q4 2024.
  • 115 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.